T. Joseph Mattingly II

Has grant

Associate Professor and Vice Chair of Research

University of Utah College of Pharmacy

United States

Research Interests

Explore related searches

Professors in United States

About

T. Joseph Mattingly II is an Associate Professor and Vice Chair of Research at The University of Utah College of Pharmacy in the United States. His research interests encompass treatment tolerability for various cancers, cost-effectiveness in pharmaceutical care, and health disparities in value assessments. He has authored several recent articles addressing critical issues such as drug shortages, health economics, and medication procurement reforms.

Recent Grants

Grant: Close

COMmunity Mistrust and Institutional Trustworthiness to advance health EQuity research (COMMIT-EQ)

Open Date: 2022-04-01

Close Date: 2023-03-31

Grant: Close

COmmunity Mistrust and Measures of Institutional Trustworthiness (COMMIT)

Open Date: 2022-01-01

Close Date: 2023-11-30

Grant: Close

Engaging an Underserved Patient Community to Inform and Improve Comparative Effectiveness Research for Hepatitis C Treatments

Open Date: 2017-01-01

Close Date: 2017-12-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (3)

Emeka Elvis Duru

University of Utah

UNITED STATES

View details

Matti Marklund

University of New South Wales

AUSTRALIA

View details

David C. Young

University of Utah Health

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

T. Joseph Mattingly II

Research Interests

Explore related searches

About

Recent Grants

Articles (20)

Effects of medication procurement reforms and extended prescription duration on medication coverage for hypertension in India’s public health system: a modelling study

Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review

Treatment tolerability associated with carboplatin dose based on actual versus adjusted body weight in patients with a body mass index ≥25 kg/m2 with advanced ovarian cancer

Substitute Economics and the Threat of Artificial Intelligence Providing Pharmaceutical Care

Advancing Federal Coordination to Address Drug Shortages

Costs of Illness for Huntington’s Disease: A Systematic Review

Cost of long-term care and balancing caregiver wellbeing: a narrative review

Consideration for Health Disparities in Value Assessment Frameworks

A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments

Interpreting 340B contract pharmacy growth: who really benefits?

Donations wanted: Assessing online medical crowdfunding campaigns created for dementia care

Who Owns This Nursing Home? The Role of Private Equity in Long-Term Care

Exploring pharmacy student experiences with student debt and perspectives on future burnout and loan relief.

“Worth it if you could afford it”: Patient perspectives on integrating real‐time benefit tools into drug cost conversations

The economics of advanced and unresectable hepatocellular carcinoma

A review of caregiver costs included in cost-of-illness studies

Direct‐to‐consumer advertising and the advancement of the quadruple aim: A narrative review

Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies

A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment

Understanding authorized generics—A review of the published clinical data

Collaborators (3)

Emeka Elvis Duru

Matti Marklund

David C. Young

Make your next move.